Biotech News

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.2026-06-25 13:46 ESTCompany update

RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant

Open original release

Related news

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

View all latest news

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States